News

All of Ferrer’s information, just a click away

normal

Details of Clinical Trial ADORE for Amyotrophic Lateral Sclerosis (ALS)

.

Thu, 02/24/2022 - 09:17

Ferrer announces distribution agreement with United Therapeutics for treprostinil inhalation solution for pulmonary hypertension associated with interstitial lung disease

.

Wed, 02/23/2022 - 15:24

Ferrer becomes a B Corp for its positive impact in society

.

Tue, 01/25/2022 - 15:06

Ferrer joins Barcelona + B, a project to bring the business community closer to the SDGs

.

Mon, 11/29/2021 - 17:47

First patient enrolled in Ferrer's FNP122 ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS) treatment

.

Mon, 11/08/2021 - 14:12

World Stroke Day - "Another one?" campaign

.

Fri, 10/29/2021 - 06:53

Ferrer signs license agreement to develop an oral formulation treatment for patients with ALS

.

Wed, 10/20/2021 - 09:29

The Ferrer team let loose their activism in the first Days for Good

.

Fri, 10/08/2021 - 09:47

Ferrer launches third edition of Ferrer 4 Future program

.

Tue, 07/06/2021 - 06:31

Ferrer certified as a great place to work, with people at the center of its cultural transformation

.

Fri, 06/25/2021 - 12:57

For requests for interviews or information, please contact the Communications Department

alternatively, please dial +34 936 003 779

See more

Business Development